Rubicon Research initial public offering (IPO) is all set to open for subscription today, Thursday, October 9. The mainboard issue will remain till Monday, October 13.
Rubicon Research is a pharmaceutical formulations company that emphasizes research, development, and innovation. Its portfolio features an expanding range of specialty medicines and drug-device combination products, with a strong focus on regulated markets, particularly the United States.
Rubicon Research IPO subscription status
The subscription status of Rubicon Research IPO will begin at 10:00 am on Thursday, October 9.
Rubicon Research IPO Review
Brokerage firm Arihant Capital has given ‘subscribe’ rating, said, “Rubicon Research Ltd is an integrated pharmaceutical product development company with a strong presence in the U.S. generics and specialty markets. The company focuses on complex generics, specialty formulations, and value-added products, supported by robust in-house R&D and regulatory capabilities. With over 65 commercialized products, a deep development pipeline, and manufacturing facilities in India serving global markets, Rubicon combines innovation with cost efficiency. Its recent entry into the specialty branded space through the Validus acquisition enhances growth visibility, while its data-driven portfolio strategy and integrated supply chain ensure sustainable profitability and scalability. At the upper band of INR 485, the issue is valued at a P/E ratio of ~60x, based on annualized PAT of FY25 EPS of INR 8.2. OFS of INR 8,775 Mn (18.09 Mn shares) and a Fresh Issue of INR 5,000 Mn (10.31 Mn shares). We are recommending a “Subscribe” rating for this issue.”
(This is a developing story)
Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
